News | Radiopharmaceuticals and Tracers | July 30, 2015

Navidea, Mass General Evaluate Nuclear Imaging Agent for Vulnerable Plaque Detection

SPECT/CT agent could be valuable tool for finding cardiovascular disease, especially in HIV+ patients

Navidea, Mass General, Tc99m-tilmanocept, vulnerable plaque, cardiovascular disease, Harvard

July 30, 2015 — Navidea Biopharmaceuticals Inc. announced plans to move forward with a joint study of the ability of Tc99m-tilmanocept, a Manocept platform product, to localize in high-risk atherosclerotic plaques. The study — funded through a $321,000 Phase 1 Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), National Institute of Health (NIH) — will be conducted with Massachusetts General Hospital (MGH) and Harvard Medical School.

The specific plaques being studied are rich in CD206-expressing macrophages and are at high-risk for near-term rupture, resulting in myocardial infarctions, sudden cardiac death and strokes, accumulatively the leading cause of death in the United States.

The consequences of atherosclerosis and subsequent cardiovascular disease (CVD), while severe in all populations, are particularly concentrated in HIV+ patients. “This Phase 1 pilot study may provide evidence that Tc99m-tilmanocept localizes in atherosclerotic plaques which would enable potential development of a diagnostic imaging agent that could benefit not only HIV+ patients but millions of people,” said Michael Tomblyn, M.D., Navidea’s chief medical officer.

“HIV infected patients suffer disproportionally from atherosclerosis and CVD,” commented Steven Grinspoon, M.D., professor of medicine at Harvard Medical School, director MGH Program in Nutritional Metabolism, co-director of the Nutrition Obesity Research Center at Harvard and the study’s lead investigator. “There exists a profound and highly significant unmet need for means to better diagnose and treat atherosclerosis in all patients but particularly so in HIV patients. Manocept’s proven specificity for CD206 presents a clinically exploitable target with potential to achieve significant diagnostic and therapeutic results where few other approaches have progressed.”

Recently, it has been observed that CD206-expressing macrophages densely populate vulnerable plaques or thin cap fibroatheromas (TCFA) but not other kinds (i.e., stable) of atherosclerotic plaques. A primary goal for this grant involves an approved clinical investigation of up to 18 individuals with and without aortic and high risk coronary atherosclerotic plaques, and with and without HIV infection to determine the feasibility of 99mTc-tilmanocept to image high-risk plaque by single-photon emission computed tomography (SPECT)/CT. Results have the potential to provide evidence of the potential of 99mTc-tilmanocept to accumulate in high-risk morphology plaques, the ability to make preliminary comparisons of aortic 99mTc-tilmanocept uptake by SPECT/CT in each group, and to evaluate the ability of 99mTc-tilmanocept to identify the same aortic atherosclerotic plaques that are identified by contrast enhanced coronary computed tomography angiography (CCTA) and/or PET/CT.

For more information: www.navidea.com

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init